BSLN — Basilea Pharmaceutica AG, Allschwil Share News
0.000.00%
Last trade - 00:00- CH₣888.06m
- CH₣785.65m
- CH₣232.38m
Brief: Basilea Announces Sale Of Preclinical Oncology Program To Nodus Oncology
Swiss stocks - Factors to watch on September 7
Brief: Reg-Basilea Reports H1 Diluted Loss Per Share of CHF 1.03
Swiss stocks - Factors to watch on August 16
Brief: Basilea Announces Zevtera (Ceftobiprole) Marketing Authorization In Brazil
Swiss stocks - Factors to watch on July 12
Swiss stocks - Factors to watch on June 29
Basilea climbs in premarket on positive results from ERADICATE study
Brief: Basilea Plans To Submit A New Drug Application (Nda) In The U.S. Around Year End 2022
Swiss stocks - Factors to watch on June 28
Brief: Basilea Reports Progress On Implementation Of Its Strategy To Focus On Anti-Infectives
Brief: Basilea Announces Approval For Additional Formulation Of Antifungal Cresemba In China
Brief: Basilea Pharmaceutica Announces Cresemba® Sales In Asia Pacific Region Trigger Sales Milestone Payment For This Region
Brief: Basilea Pharmaceutica: Cresemba Sales In Asia Pacific Trigger Milestone Payment From Pfizer
Swiss stocks - Factors to watch on June 17
Swiss stocks - Factors to watch on April 13
Swiss stocks - Factors to watch on January 11
Swiss stocks - Factors to watch on January 6
Brief: Basilea's Partner Asahi Kasei Pharma Files New Drug Application In Japan